Multiple myeloma (MM) patients who have resistant or refractory disease need to be treated. For a study, researchers examined the function of the combination of bendamustine, pomalidomide, and dexamethasone in the phase II investigation.
About 28 patients were enlisted between February 2020 and December 2021. For a maximum of 6 cycles, patients were given the following regimen: bendamustine 120 mg/m2 day 1, pomalidomide 3 mg days 1-21, and dexamethasone 40 mg days 1, 8, 11, and 22. The patients’ median age (interquartile range) was 54 (30-76), and 15 (53.6%) of them were male. A median (interquartile range) of 3 (2 to 6) previous lines of therapy had been administered to the patients, and 85.7% of them were resistant to both lenalidomide and bortezomib.
The overall response rate (ORR), which is defined as a greater or equal to partial response after at least 3 cycles, served as the primary endpoint. Toxicity, progression-free survival (PFS), time to progression, and overall survival (OS) were secondary goals. An examination of intent-to-treat was conducted. An ORR of 57.6% was attained. More patients with extramedullary myeloma responded to treatment. The median PFS and OS were 6.2 and 9.7 months, respectively, during a median follow-up of 8.6 months. Manageable toxicity, mostly hematological (neutropenia, 46.4%; anaemia, 42.8%; and thrombocytopenia, 7.1%).
The severely pretreated, lenalidomide-refractory myeloma population may benefit from the unique combination of bendamustine, pomalidomide, and dexamethasone.